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patients (26.0%-42.5% p< 0.0001), while reductions in mean SABA fills were also 
observed in Severe patients (20.1%; p= 0.0328). ConClusions: Omalizumab ini-
tiation was associated with significant reduction in PACE and MU in patients with 
moderate or severe persistent asthma.
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objeCtives: The purpose of this study is to compare the frequency of exacer-
bations between aclidinium and tiotropium in patients with chronic obstructive 
pulmonary disease (COPD). Methods: Through a systematic literature search in 
Medline (PubMed), we included randomized controlled trials that evaluated the 
exacerbation frequency of aclidinium 200µg and 400µg twice a day and tiotropium 
18µg once a day regimens compared to placebo. Inclusion criteria were at least 
12 weeks of treatment from January 1990 to January 2014, an age over 40, current 
or former smokers, and diagnosis with moderate to very severe COPD. The main 
outcome is the frequency of exacerbation. Indirect comparison analysis was per-
formed to estimate the odds ratio of exacerbation between aclidinium and tiotro-
pium. Results: After screening 278 full-text articles, we identified 19 clinical trials 
that total 19,741 COPD patients were participated: 3 trials of aclidinium 200µg and 
400µg BID and 16 trials of tiotropium 18µg QD. tiotropium 18µg was associated with 
a significant reduction in exacerbation compared with placebo (OR 0.90; 95% CI 0.84 
to 0.96). Other two anticholinergic agents showed comparable effects in reducing 
exacerbation compared with placebo: aclidinium 200µg (OR 0.73; 95% CI 0.53 to 1.01) 
and aclidinium 400µg (OR 0.72; 95% CI 0.52 to 1.00). Aclidinium 200µg (OR 0.84; 95% 
CI 0.603-1.167) and aclidinium 400µg (OR 0.83; 95% CI 0.592 -1.156) BID showed the 
similar frequency of exacerbation to tiotropium 18µg QD. ConClusions: Our study 
substantiates that tiotropium 18µg provides superior effects on lowering the risk of 
exacerbation compared with placebo but there was no significant difference in the 
frequency of exacerbations between aclidinium and tiotropium.
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objeCtives: To estimate the number of users of Theophylline (ATC: R03DA04) 
and Doxofylline (ATC: R03DA11) for the treatment of chronic asthma in adults, 
in the Marche Region. Moreover, we wanted to estimate the cost of the two treat-
ments, taking into account the prescriptions of other drugs associated with 
them. Methods: The drug prescriptions were extracted from the Information 
System of the Pharmaceutical Prescriptions of the Marche Region (PHARM), con-
taining all the recipes sent by pharmacies within the region and reimbursed by the 
National Health System. The number of prescriptions per year has been obtained 
by selecting all the recipes for each ATC code in the years 2008-2012, while the 
number of users has been estimated by identifying the subjects who received at 
least one prescription of the ATC codes of interest. The number of concomitant 
prescriptions was estimated by selecting all the recipes for potentially associated 
ATC, dispenced between 5 days before and 5 days following the prescription of ATC 
codes. The price of prescriptions has been calculated using the information “price” 
contained in the PHARM record. Results: For both drugs, the users are approxi-
mately 5,000 per year in the study period. Theophylline had a mean base price lower 
than Doxofylline (4.81€ vs 6.37€ per prescription); however, Theophylline was more 
associated than Doxofylline (34.4% vs 23.7%) with other drugs for the treatment of 
Asthma. Consequently, the total treatment cost for Theophylline was equal to 33.65€ 
vs a total cost for Doxofylline equal to 22.49€ (+ 49.6%). ConClusions: The PHARM 
allows the estimate of drugs’ utilization, taking into account the overall patient’s 
treatment plan. In our study, the prescription of the first ATC code is more associ-
ated with prescriptions of other drugs, and this implies an increasing in the cost of 
the treatment plan despite a lower average initial price.
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objeCtives: A database research was conducted to investigate the incidence of 
anaphylaxis/shock using a Japanese health-claims database (HDB). In addition, 
the prescription rate of self-injection epinephrine was investigated among those 
patients with anaphylaxis for the management of future reactions. Methods: 
A Japanese HDB which contains approximately 1.8 million subjects covered by 
employment-based health insurance (MinaCare Co. Ltd) was used for this retrospec-
tive study. In order to identify actual anaphylaxis/shock precisely, diagnosis recorded 
in the claims based on ICD-10 code (T78.0, T78.2 and T88.6) was combined with claim 
records of medical practice and prescriptions. Specifically, prescription for epineph-
rine/adrenaline or oxygen inhalation therapy was required for “anaphylactic shock” 
and the use of an infusion therapy or venous catheter was required for detect-
ing “anaphylaxis (except for anaphylactic shock)”. For this study, the data associ-
ated with events occurring in fiscal years 2010 to 2013 (2010/4/1 to 2013/3/31) were 
included. Results: Of approximately 2.9 million person-years of observations, 13.3 
anaphylactic shock events per 100,000 person-years (crude rate) were identified. The 
rate was 42.9 per 100,000 person-years when non-shock anaphylaxis events were 
considered. The age-specific anaphylactic shock event rates (per 100,000 person-
years) were: 27.6 (0-6 years), 12.8 (7-12 years), 11.0 (13-18 years), and 11.9 (> 18 years). 
Among the 389 anaphylactic shock events, etiologies of anaphylaxis were food 113 
objeCtives: To assess the relative efficacy of umeclidinium bromide 62.5 mcg OD 
(UMEC) versus tiotropium bromide 18 mcg OD (TIO), aclidinium bromide 400 mcg 
BID (AB) and glycopyrronium bromide 50 mcg OD (GLYCO). Methods: A systematic 
literature review was performed to identify RCTs ≥ 12 weeks duration comparing 
TIO, AB, GLYCO or UMEC to placebo in adult patients with COPD. Random effects 
meta-analyses were performed by pooling results of each treatment vs. placebo 
on change from baseline at 12 and 24 weeks in trough FEV1, SGRQ total score, TDI 
focal score and rescue medication use. The results were synthesized by using an 
indirect treatment comparison (ITC) within a frequentist framework based on the 
Bucher method. Scenario analyses were performed to evaluate the robustness of 
the results to variations in the included studies and assumptions. Results: At 12 
weeks, ITC results show that treatment with UMEC resulted in a comparable but 
numerically higher change from baseline in trough FEV1 compared to TIO [18.06mL 
(95%CI: -19.11, 55.23, p= 0.341)], AB [35.77mL (95%CI: -7.84, 79.38, p= 0.108)] and GLYCO 
[27.86mL (95%CI: -8.74, 64.45, p= 0.136)]. At 24 weeks, UMEC resulted in comparable 
trough FEV1 values vs. TIO (p= 0.854), AB (p= 0.663) and GLYCO (p= 0.777). UMEC also 
resulted in comparable TDI focal scores and rescue medication use at both time 
points compared with TIO, AB and GLYCO. UMEC resulted in numerically lower 
(better) change from baseline at 12 weeks in SGRQ total score compared with TIO 
[-2.65 (95%CI: -7.09, 1.79, p= 0.242)], AB [-2.68 (95%CI: -7.12, 1.75, p= 0.235)] and GLYCO 
[-2.15 (95%CI: -6.60, 2. 31, p= 0.345)]. At 24 weeks there was no statistically significant 
difference in change from baseline in SGRQ total score between UMEC, TIO, AB and 
GLYCO. ConClusions: UMEC showed comparable efficacy to TIO, AB and GLYCO 
on trough FEV1, SGRQ, TDI and rescue medication use at 12 and 24 weeks.
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objeCtives: To compare the effectiveness of omalizumab versus standard of care 
(SOC) based on randomized controlled trials (RCTs) compared with ‘real-world’, 
single cohort, observational studies that assess patients ‘before and after’ the use of 
omalizumab. Methods: A systematic literature review was conducted to identify 
RCTs and observational studies that assessed omalizumab in patients with severe 
persistent allergic asthma. Study and patient characteristics, outcome definitions, 
and differences in baseline risk and observed study effects were compared in terms 
of exacerbations and hospitalizations across the RCTs and observational stud-
ies. Results: 11 RCTs and 24 observational studies were identified. A wide range 
of clinically significant exacerbation rates was observed across RCTs in terms of 
baseline risk (SOC: 0.40–2.86) and the treatment effect (rate ratio [RR]: 0.39–0.75). This 
differed from observational studies in terms of baseline risk (before omalizumab: 
3.48–6.00) and the treatment effect (RRs: 0.12–0.46). A limited range of severe exac-
erbation rates was observed in RCTs regarding baseline risk (SOC: 0.42–0.48) and the 
treatment effect (RR: 0.50–0.56). However, considerable differences were identified 
in observational studies in terms of baseline risk (before omalizumab: 2.20–4.50) 
and the treatment effect (RR: 0.05–0.39). In terms of hospitalization rates, a limited 
range was observed for RCTs with respect to baseline risk (SOC: 0.12–0.17) and the 
treatment effect (RR: 0.12–0.54). Again, a wider range was observed across the obser-
vational studies in terms of baseline risk (before omalizumab: 0.32–4.45) and the 
treatment effect (RR: 0.09–0.71). ConClusions: ‘Real-world’ evidence reinforces 
the efficacy of omalizumab in patients with severe allergic asthma derived from 
RCTs, although differences in potential treatment effect modifiers were identified. 
Patients in observational studies may represent a more severe population compared 
with those in RCTs.
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objeCtives: Poor asthma control is associated with increased health care cost 
in patients with moderate or severe asthma. Here we evaluate the impact of 
omalizumab on poor asthma control events (PACE) and medication utilisation 
(MU) in a case-crossover study of US patients with moderate or severe persistent 
asthma. Methods: Truven MarketScan database was used to compare PACE 
(hospitalisation, ER visit, corticosteroid [CS] burst or ≥ 7 short-acting beta-agonist 
[SABA] fills) and MU for 1 year pre/post omalizumab exposure, during the period 
1-January-2007 to 30-September-2012. Included in the analysis were patients aged 
≥ 12 years who had 1 inpatient or 2 outpatient Asthma claims (ICD-9= 493. XX) and 
used omalizumab continuously for 1 year, with 2 years continuous coverage (1 year 
pre/post omalizumab index date). Patients were categorized as Moderate or Severe 
based on their most recent 8 weeks of continuous, NHLBI-guideline-recommended, 
therapy preceding omalizumab. Results: In total, 429 patients (mean age, 46.6 
years; female, 59.0%; Moderate= 340, Severe= 89) were included in the analysis. 
Omalizumab was associated with reductions in proportions of All, Moderate, and 
Severe asthma patients with PACE (41.3%, 48.3%, 17.2%, respectively; all p< 0.05). 
Specifically, reductions in patients with ≥ 1 asthma-related hospitalisation, ≥ 1 
asthma-related ER visit, ≥ 2 CS bursts, and ≥ 7 SABA fills in the Moderate group 
(Moderate: 55.9%, 77.8%, 53.8%, and 40.6%, respectively; all p≤ 0.0196) drove reduc-
tions in All patients (all p≤ 0.0159). Reductions in patients with ≥ 1 OCS fill and ≥ 1 
SABA fill were observed in All and Moderate patients (20.3%–26.1%; all p< 0.0001); 
reductions in mean OCS fills and mean SABA fills were observed in All and Moderate 
